Back to Search
Start Over
Are ketogenic diets promising for Alzheimer’s disease? A translational review
- Source :
- Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-10 (2020), Alzheimer's Research & Therapy
- Publication Year :
- 2020
- Publisher :
- BMC, 2020.
-
Abstract
- Background Brain amyloid deposition and neurofibrillary tangles in Alzheimer’s disease (AD) are associated with complex neuroinflammatory reactions such as microglial activation and cytokine production. Glucose metabolism is closely related to neuroinflammation. Ketogenic diets (KDs) include a high amount of fat, low carbohydrate and medium-chain triglyceride (MCT) intake. KDs lead to the production of ketone bodies to fuel the brain, in the absence of glucose. These nutritional interventions are validated treatments of pharmacoresistant epilepsy, consequently leading to a better intellectual development in epileptic children. In neurodegenerative diseases and cognitive decline, potential benefits of KD were previously pointed out, but the published evidence remains scarce. The main objective of this review was to critically examine the evidence regarding KD or MCT intake effects both in AD and ageing animal models and in humans. Main body We conducted a review based on a systematic search of interventional trials published from January 2000 to March 2019 found on MEDLINE and Cochrane databases. Overall, 11 animal and 11 human studies were included in the present review. In preclinical studies, this review revealed an improvement of cognition and motor function in AD mouse model and ageing animals. However, the KD and ketone supplementation were also associated with significant weight loss. In human studies, most of the published articles showed a significant improvement of cognitive outcomes (global cognition, memory and executive functions) with ketone supplementation or KD, regardless of the severity of cognitive impairments previously detected. Both interventions seemed acceptable and efficient to achieve ketosis. Conclusion The KD or MCT intake might be promising ways to alter cognitive symptoms in AD, especially at the prodromal stage of the disease. The need for efficient disease-modifying strategies suggests to pursue further KD interventional studies to assess the efficacy, the adherence to this diet and the potential adverse effects of these nutritional approaches.
- Subjects :
- Adult
Male
0301 basic medicine
medicine.medical_specialty
Neurology
Cognitive Neuroscience
medicine.medical_treatment
Review
Disease
Bioinformatics
lcsh:RC346-429
lcsh:RC321-571
Brain metabolism
03 medical and health sciences
Cognition
0302 clinical medicine
Alzheimer Disease
Weight loss
medicine
Animals
Humans
Cognitive Dysfunction
Cognitive decline
lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry
lcsh:Neurology. Diseases of the nervous system
business.industry
Ketogenic diet
medicine.disease
Animal models
030104 developmental biology
Diabetes Mellitus, Type 2
Ketone bodies
Neurology (clinical)
Ketosis
medicine.symptom
Diet, Ketogenic
business
Alzheimer’s disease
030217 neurology & neurosurgery
Subjects
Details
- Language :
- English
- ISSN :
- 17589193
- Volume :
- 12
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Alzheimer’s Research & Therapy
- Accession number :
- edsair.doi.dedup.....518fcdb72be8ba58aada31f7a897a85e